CLOVERLEAF BIO, INC.

NEW HAVEN, CT · Biotech · Private

Engineered tRNA therapeutics containing 5-fluorouracil to inhibit tRNA-modifying enzymes in hepatocellular carcinoma

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026

Sector: Biotech
Headquarters: NEW HAVEN, CT
Latest Form D: $14.8M, Sep 2026
Total capital: $15.6M

Federal grants: $400K; 1 award · 2025; Rank in peer group#353 of 502
Private capital raised: $14.8M; 1 Form D · last Sep 2026; 2 months since last filing
Federal contracts: $355K; 1 award · Health and Human S; Rank in Biotech#248 of 4373
Granted patents: 0; 1 pending

Capital timeline

Latest events

Sep 2026Private capital raisedForm D · SEC · 1st filing$14.8M
Sep 2025Federal contractHealth and Human S · SBIR FY25 Concept Award: Development Of Engineered Trna Therapeutics For Clear Cell Renal Cell Carcinoma$355K
Jun 2025Federal grantHealth and Human S · Phase II · Developing engineered inhibitors of tRNA modifying enzymes$400K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

15months

from CLOVERLEAF BIO, INC.’s first federal award to its first private round.

First federal award · Jun 2025: Health and Human S · $400K
First Form D · Sep 2026: $14.8M · 1st Form D
Awards before first raise: 2 awards

An association in public records, not a cause or a prediction.

Standing among 502 peers

Line = median

Biotech · Molecule

Federal grantsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 0 granted of 1

PendingRNA-BASED INHIBITORS OF tRNA MODIFYING ENZYMESUSPTOApplication 63691051

CYTOBIOSCIENCE INCSimilar federal contract value in Biotech · $387K in contracts
SIGNABLOK, INC.Similar federal contract value in Biotech · $370K in contracts
NUVOX PHARMA, L.L.C.Similar federal contract value in Biotech · $356K in contracts
MATRISOME BIO, INC.Similar federal contract value in Biotech · $354K in contracts
Longevity Biotech, IncSimilar federal contract value in Biotech · $348K in contracts
GENOMIC EXPRESSION INCSimilar federal contract value in Biotech · $340K in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.